Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17

Cancer Research

Volumn 66, Issue 16, 2006, Pages 8083-8090

  Franovic, Aleksandra ^a   Robert, Isabelle ^a   Smith, Karlene ^a   Kurban, Ghada ^b   Pause, Arnim ^b   Gunaratnam, Lakshman ^a   Lee, Stephen ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; METALLOPROTEINASE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; INFLAMMATION; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADAM PROTEINS; CARCINOMA, RENAL CELL; CELL DIVISION; CELL LINE, TUMOR; GENE SILENCING; HIPPEL-LINDAU DISEASE; HUMANS; KIDNEY NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 33748037366     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1595     Document Type: Article

References (48)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Bernards R, Weinberg RA. Metastasis genes: a progression puzzle. Nature 2002;418:823.
3. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99.
4. Brattain MG, Howell G, Sun LZ, Willson JK. Growth factor balance and tumor progression. Curr Opin Oncol 1994;6:77-81.
5. Pardee AB. G1 events and regulation of cell proliferation. Science 1989;246:603-8.
6. Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature 1985;313:745-7.
7. Humes HD, Beals TF, Cieslinski DA, Sanchez IO, Page TP. Effects of transforming growth factor-β, transforming growth factor-α, and other growth factors on renal proximal tubule cells. Lab Invest 1991;64:538-45.
8. Gomella LG, Sargent ER, Wade TP, Anglard P, Linehan WM, Kasid A. Expression of transforming growth factor α in normal human adult kidney and enhanced expression of transforming growth factors α and β1 in renal cell carcinoma. Cancer Res 1989;49:6972-5.
9. de Paulsen N, Brychzy A, Fournier MC, et al. Role of transforming growth factor-α in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Nail Acad Sci U S A 2001;98:1387-92.
10. Knebelmann B, Ananth S, Cohen HT, Sukhatme VP. Transforming growth factor α is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 1998;58: 226-31.
11. Atlas I, Mendelsohn J, Baselga J, Fair WR, Masui H, Kumar R. Growth regulation of human renal carcinoma cells: role of transforming growth factor α. Cancer Res 1992;52:3335-9.
12. Mydlo JH, Michaeli J, Cordon-Cardo C, Goldenberg AS, Heston WD, Fair WR. Expression of transforming growth factor α and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res 1989;49:3407-11.
13. Petrides PE, Bock S, Bovens J, Hofmann R, Jakse G. Modulation of pro-epidermal growth factor, protransforming growth factor α and epidermal growth factor receptor gene expression in human renal carcinomas. Cancer Res 1990;50:3934-9.
14. Gunaratnam L, Morley M, Franovic A, et al. Hypoxia inducible factor activates the transforming growth factor-{α}/epidermal growth factor receptor growth stimulatory pathway in VHL-/- renal cell carcinoma cells. J Biol Chem 2003;278:44966-74.
15. Smith K, Gunaratnam L, Morley M, Franovic A, Mekhail K, Lee S. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res 2005;65:5221-30.
16. Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in mammalian development Science 1998;282:1281-4.
17. Sunnarborg SW, Hinkle CL, Stevenson M, et al. Tumor necrosis factor-α converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem 2002;277:12838-45.
18. Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J. TACE is required for the activation of the EGFR by TGF-α in tumors. EMBO J 2003;22:1114-24.
19. Yang H, Jiang D, Li W, Liang J, Gentry LE, Brattain MG. Defective cleavage of membrane bound TGF leads to enhanced activation of the EGF receptor in malignant cells. Oncogene 2000;19:1901-14.
20. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003;17:7-30.
21. Lovering F, Zhang Y. Therapeutic potential of TACE inhibitors in stroke. Curr Drug Targets CNS Neurol Disord 2005;4:161-8.
22. Doggrell SA. TACE inhibition: a new approach to treating inflammation. Expert Opin Investig Drugs 2002; 11:1003-6.
23. Shao MX, Ueki IF, Nadel JA. Tumor necrosis factor α-converting enzyme mediates MUC5AC mucin expression in cultured human airway epithelial cells. Proc Natl Acad Sci U S A 2003;100:11618-23.
24. Bonicalzi M-E, Groulx I, de Paulsen N, Lee S. Role of exon 2-encoded β-domain of the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2001; 276:1407-16.
25. Lieubeau-Teillet B, Rak J, Jothy S, Iliopoulos O, Kaelin W, Kerbel RS. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res 1998;58:4957-62.
26. Iliopoulos O, Kibel A, Gray S, Kaelin WG, Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1995;1:822-6.
27. Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 1995;273:564-70.
28. Kaelin WG, Jr., Iliopoulos O, Lonergan KM, Ohh M. Functions of the von Hippel-Lindau tumour suppressor protein. J Intern Med 1998;243:535-9.
29. Pause A, Lee S, Lonergan KM, Klausner RD. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci U S A 1998;95:993-8.
30. Kurban G, Hudon V, Duplan E, Ohh M, Pause A. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res 2006;66:1313-9.
31. Ohh M, Yauch RL, Lonergan KM, et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998;1:959-68.
32. Black RA. Tumor necrosis factor-[α] converting enzyme. Int J Biochem Cell Biol 2002;34:1-5.
33. Ikemoto S, Yoshida N, Narita K, et al. Role of tumor-associated macrophages in renal cell carcinoma. Oncol Rep 2003;10:1843-9.
34. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
35. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72.
36. Barrandon Y, Green H. Cell migration is essential for sustained growth of keratinocyte colonies: the roles of transforming growth factor-[α] and epidermal growth factor. Cell 1987;50:1131-7.
37. Maheshwari G, Wiley HS, Lauffenburger DA. Autocrine epidermal growth factor signaling stimulates directionally persistent mammary epithelial cell migration. J Cell Biol 2001;155:1123-8.
38. Sewell JM, Smyth JF, Langdon SP. Hole of TGF[α] stimulation of the ERK, PI3 kinase and PLC[γ] pathways in ovarian cancer growth and migration. Exp Cell Res 2005;304:305-16.
39. Lamszus K, Brockmann MA, Eckerich C, et al. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin Cancer Res 2005;11:4934-40.
40. Nagano O, Murakami D, Hartmann D, et al. Cell-matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca2+ influx and PKC activation. J Cell Biol 2004;165:893-902.
41. Beer S, Oleszewski M, Gutwein P, Geiger C, Altevogt P. Metalloproteinase-mediated release of the ectodomain of L1 adhesion molecule. J Cell Sci 1999;112: 2667-75.
42. Huang J, Bridges LC, White JM. Selective modulation of integrin-mediated cell migration by distinct ADAM family members. Mol Biol Cell 2005;16:4982-91.
43. Bax DV, Messent AJ, Tart J, et al. Integrin {α}5{β}1 and ADAM-17 interact in vitro and co-localize in migrating HeLa cells. J Biol Chem 2004;279:22377-86.
44. Sieg DJ, Hauck CR, Ilic D, et al. FAK integrates growth-factor and integral signals to promote cell migration. Nat Cell Biol 2000;2:249-56.
45. Motzer RJ, Amato R, Todd M, et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003;21:99-101.
46. Drucker B, Bacik J, Ginsberg M, et al. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 2003;21:341-50.
47. Perera AD, Kleymenova EV, Walker CL. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma. Clin Cancer Res 2000;6:1518-23.
48. Dancey JE. Epidermal growth factor receptor and epidermal growth factor receptor therapies in renal cell carcinoma: do we need a better mouse trap? J Clin Oncol 2004;22:2975-7.